Abstract:Brain perineuronal nets (PNNs) are vital for neurocircuit stability and changes in their abundance and composition have been linked to Alzheimer's disease (AD) progression. In this work, we investigated age‐associated PNN changes in transgenic mice with tauopathy‐related AD neuropathology. 9‐month‐old PS19 (P301S) mice exhibited changes in PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) composition and abundance, but not the underlying CS proteoglycan (CSPG) core proteins, in association with pTau, gliosis, and neurodegeneration. In contrast, Tau4RTg2652 mice showed stable PNNs despite pTau accumulation, emphasizing the importance of neuroinflammation on PNN glycan integrity in AD. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by clinical symptoms of memory and cognitive deficiencies. Postmortem evaluation of AD brain tissue shows proteinopathy that closely associate with the progression of this dementing disorder, including the accumulation of extracellular beta amyloid (Aβ) and intracellular hyperphosphorylated tau (pTau) with neurofibrillary tangles (NFTs). Current therapies targeting Aβ have limited clinical efficacy and life‐threatening side effects and highlight the need for alternative treatments targeting pTau and other pathophysiologic mechanisms driving AD pathogenesis. The brain's extracellular matrices (ECM), particularly perineuronal nets (PNNs), play a crucial role in brain functioning and neurocircuit stability, and reorganization of these unique PNN matrices has been associated with the progression of AD and accumulation of pTau in humans. We hypothesize that AD‐associated changes in PNNs may in part be driven by the accumulation of pTau within the brain. In this work, we investigated whether the presence of pTau influenced PNN structural integrity and PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) compositional changes in two transgenic mouse models expressing tauopathy‐related AD pathology, PS19 (P301S) and Tau4RTg2652 mice. We show that PS19 mice exhibit an age‐dependent loss of hippocampal PNN CS‐GAGs, but not the underlying aggrecan core protein structures, in association with pTau accumulation, gliosis, and neurodegeneration. The loss of PNN CS‐GAGs were linked to shifts in CS‐GAG sulfation patterns to favor the neuroregenerative isomer, 2S6S‐CS. Conversely, Tau4RTg2652 mice exhibit stable PNN structures and normal CS‐GAG isomer composition despite robust pTau accumulation, suggesting a critical interaction between neuronal PNN glycan integrity and neighboring glial cell activation. Overall, our findings provide insights into the complex relationship between PNN CS‐GAGs, pTau pathology, gliosis, and neurodegeneration in mouse models of tauopathy, and offer new therapeutic insights and targets for AD treatment.

Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases

AβPP-tau-HAS1 Β PP-tau-HAS1 Axis Trigger HAS1-related Nuclear Speckles and Gene Transcription in Alzheimer's ' S Disease

AβPP-tau-HAS1 axis trigger HAS1-related nuclear speckles and gene transcription in Alzheimer's disease

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Expression of P301L-hTau in Mouse MEC Induces Hippocampus-Dependent Memory Deficit

Interneuron Accumulation of Phosphorylated Tau Impairs Adult Hippocampal Neurogenesis by Suppressing GABAergic Transmission.

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

Tau Accumulation Triggers STAT 1‐dependent Memory Deficits by Suppressing NMDA Receptor Expression

Heme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons.

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

An HDAC6-dependent Surveillance Mechanism Suppresses Tau-Mediated Neurodegeneration and Cognitive Decline

P301S‐hTau Acetylates KEAP1 to Trigger Synaptic Toxicity Via Inhibiting NRF2/ARE Pathway: A Novel Mechanism Underlying Htau‐induced Synaptic Toxicities

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

Overexpression of 14-3-3ζ Promotes Tau Phosphorylation at Ser262 and Accelerates Proteosomal Degradation of Synaptophysin in Rat Primary Hippocampal Neurons

Cleavage of Tau by Asparagine Endopeptidase Mediates the Neurofibrillary Pathology in Alzheimer's Disease